Meta Pixel

News and Announcements

Novapep’s Pioneering Approach to Treating Inflammatory Bowel Diseases

  • Published October 15, 2024 7:42AM UTC
  • Publisher Maan Perez
  • Categories Executive Interviews

Join Jay Hennock, CEO of Novapep, as he unveils the company’s mission to address unmet medical needs through peptide-based therapies.

Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (a US$20 billion market) and superior to corticosteroids, but with minimal expected side effects.

This video provides a compelling overview of their research and development efforts, focusing on inflammatory skin disorders, bowel disease, and sepsis, and their impact on global health.

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Capital Insights
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain

In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]

Join over 45,000+ sophisticated investors

Join Now